Loading patent…
AssigneesPostech Academy-Industry Foundation, Korea Food & Drug Administration
InventorsJung Hwan Lee, Young Chan Chae, Youngdong Kim, Hyungu Kang, Jong Hun Im, Jong In Kim, Ki Seok Kim, Sung Key Jang, Il Ung Oh, Min Jeong Choi, Won Jun Kang
Estimating the term…
Disclosed are a DNA aptamer specifically binding to the Her2 (ERBB2) receptor involved in the onset of breast cancer, a composition for the suppression of cancer metastasis comprising the same as an active ingredient, and a composition for the diagnosis of cancer comprising the same as an active ingredient. Due to its binding mechanism being different from that of the conventional antibody, the aptamer can be effectively used for suppressing cancer metastasis and diagnosing cancer.
An ERBB2 aptamer, which specifically binds to ERBB2, and comprises 40 to 100 nucleotides comprising a nucleotide sequence selected from the group consisting of SEQ ID NOS:
Dependencies are inferred from the claim text.